Swiss major Roche buys US firm InterMune for £5bn
August 25 , 2014
Roche, the Swiss pharma major, is buying California-based firm InterMune for £5bn ($8.3bn), according to media reports.
The US company is known for its medicines for treating serious lung conditions.
In 2009, Roche had bought a part of Genentech for around $47bn. Roche will reportedly pay $78 a share in InterMune.
The drugs sector has seen a series of mergers in the recent past. Among the major deals, American drug company AbbVie bought British pharmaceutical firm Shire for around £32bn.